Macrophage-derived CCL18 promotes osteosarcoma proliferation and migration by upregulating the expression of UCA1.
Animals
Bone Neoplasms
/ genetics
Cell Line, Tumor
Cell Movement
Cell Proliferation
Chemokines, CC
/ metabolism
Gene Expression Regulation, Neoplastic
Humans
Macrophages
/ metabolism
Male
Mice, Inbred BALB C
Mice, Nude
Neoplasm Invasiveness
/ genetics
Osteosarcoma
/ genetics
RNA, Long Noncoding
/ genetics
Up-Regulation
CCL18
EP300
Macrophage
Metastasis
Osteosarcoma
UCA1
Journal
Journal of molecular medicine (Berlin, Germany)
ISSN: 1432-1440
Titre abrégé: J Mol Med (Berl)
Pays: Germany
ID NLM: 9504370
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
02
01
2018
accepted:
28
10
2018
revised:
22
10
2018
pubmed:
15
11
2018
medline:
6
5
2020
entrez:
15
11
2018
Statut:
ppublish
Résumé
Osteosarcoma (OS), which is the most common primary malignant bone tumor, has a high incidence of pulmonary metastasis. CCL18 (C-C motif chemokine ligand 18), which is secreted by tumor-associated macrophages (TAMs), has been found to be increased in various tumors and is associated with tumor metastasis. However, the role of CCL18 in OS remains unclear. Here, we evaluated the effect of CCL18 on the OS cell lines MG63 and 143B and explored its potential mechanisms. We found that CCL18 enhanced the proliferation and migration of OS cells and upregulated UCA1 through transcription factor EP300. Subsequently, we further revealed that the downstream Wnt/β-catenin signaling pathway participated in this process. In addition, the high expression of CCL18 in both tissue and serum from patients was closely related to pulmonary metastasis and poor survival in OS patients. The tumor xenograft models also showed that CCL18 promoted the metastasis of OS cells. Collectively, our study indicated that macrophage-derived CCL18 promotes OS proliferation and metastasis via the EP300/UCA1/Wnt/β-catenin pathway and that CCL18 may be used as a prognostic marker and therapeutic target of OS. KEY MESSAGES: CCL18 promotes proliferation and migration of osteosarcoma cells by EP300/ UCA1/ Wnt/β-catenin pathway. CCL18
Identifiants
pubmed: 30426155
doi: 10.1007/s00109-018-1711-0
pii: 10.1007/s00109-018-1711-0
doi:
Substances chimiques
CCL18 protein, human
0
Chemokines, CC
0
RNA, Long Noncoding
0
UCA1 RNA, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
49-61Subventions
Organisme : National Natural Science Foundation of China
ID : 81372873
Pays : International
Organisme : National Natural Science Foundation of China
ID : 81503396
Pays : International
Références
Oncotarget. 2016 Nov 29;7(48):78343-78354
pubmed: 27823976
Oncogene. 2014 May 8;33(19):2423-31
pubmed: 23728338
Cancers (Basel). 2014 Aug 13;6(3):1670-90
pubmed: 25125485
Cell Mol Life Sci. 2015 Aug;72(16):3097-113
pubmed: 25935149
J Bone Oncol. 2016 May 10;5(2):80-5
pubmed: 27335776
Cancer Lett. 2015 Nov 1;368(1):7-13
pubmed: 26276713
Cancer Sci. 2016 Nov;107(11):1581-1589
pubmed: 27560546
PLoS One. 2009 Aug 10;4(8):e6562
pubmed: 19668347
Oncol Res. 2018 Dec 27;27(1):55-64
pubmed: 29523218
PLoS One. 2016 Dec 15;11(12):e0168406
pubmed: 27977766
Am J Orthop (Belle Mead NJ). 2015 Dec;44(12):547-53
pubmed: 26665241
Cancer Cell. 2011 Apr 12;19(4):541-55
pubmed: 21481794
Eur Rev Med Pharmacol Sci. 2017 Feb;21(3):498-503
pubmed: 28239821
Oncoimmunology. 2017 Aug 24;6(9):e1331193
pubmed: 28932633
J Bone Joint Surg Am. 2016 Jun 1;98(11):916-25
pubmed: 27252436
Cancer. 2005 Sep 1;104(5):1100-9
pubmed: 16015627
Int J Oncol. 2015 Oct;47(4):1329-38
pubmed: 26238511
Oncogene. 2018 May;37(22):2903-2920
pubmed: 29515232
Melanoma Res. 2014 Aug;24(4):335-41
pubmed: 24892958
Oncotarget. 2017 Jul 25;8(44):76241-76256
pubmed: 29100308
Breast Cancer Res Treat. 2014 Nov;148(2):291-302
pubmed: 25311112
J Cancer Res Clin Oncol. 2016 Jul;142(7):1407-19
pubmed: 26341664
Oncotarget. 2015 Apr 10;6(10):7899-917
pubmed: 25760077
Mol Cancer. 2016 Sep 09;15(1):58
pubmed: 27613122
Mol Carcinog. 2016 Dec;55(12):2051-2062
pubmed: 26756176
Nat Rev Cancer. 2015 Aug;15(8):451-2
pubmed: 26422835
J Clin Oncol. 2002 Feb 1;20(3):776-90
pubmed: 11821461
Clin Dev Immunol. 2012;2012:948098
pubmed: 22778768
Tumour Biol. 2016 Mar;37(3):3461-8
pubmed: 26449829
Cancer Treat Res. 2014;162:65-92
pubmed: 25070231
RNA Biol. 2015;12(10):1094-8
pubmed: 26177256
Nature. 2011 Jun 08;475(7355):222-5
pubmed: 21654748
Cancer Immunol Res. 2017 Jul;5(7):547-559
pubmed: 28515123
Anticancer Res. 2014 Oct;34(10):5331-6
pubmed: 25275026
J Cell Sci. 2012 Dec 1;125(Pt 23):5591-6
pubmed: 23420197
Oncol Rep. 2018 Mar;39(3):1072-1080
pubmed: 29328452
Biomed Res Int. 2014;2014:230183
pubmed: 25197632
PLoS One. 2017 Jan 12;12(1):e0170042
pubmed: 28081243
Tohoku J Exp Med. 2014;233(1):25-31
pubmed: 24747338